The different benefits and side effects of nivolumab combined with ipilimumab in diverse cancer: A Protocol for Systematic Review (Q90352646)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 March 2020

edit

Language	Label	Description	Also known as
English	The different benefits and side effects of nivolumab combined with ipilimumab in diverse cancer: A Protocol for Systematic Review	scientific article published on 01 March 2020

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

32176058

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32176058%20AND%20SRC:MED&resulttype=core&format=json

retrieved

13 April 2020

review article

1 reference

stated in

Europe PubMed Central

title

The different benefits and side effects of nivolumab combined with ipilimumab in diverse cancer: A Protocol for Systematic Review (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

32176058

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32176058%20AND%20SRC:MED&resulttype=core&format=json

retrieved

13 April 2020

author name string

Hongxuan Tong

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

32176058

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32176058%20AND%20SRC:MED&resulttype=core&format=json

retrieved

13 April 2020

Yu Hao

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

32176058

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32176058%20AND%20SRC:MED&resulttype=core&format=json

retrieved

13 April 2020

Kaili Wang

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

32176058

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32176058%20AND%20SRC:MED&resulttype=core&format=json

retrieved

13 April 2020

Lekang Xiang

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

32176058

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32176058%20AND%20SRC:MED&resulttype=core&format=json

retrieved

13 April 2020

Tao Lu

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

32176058

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32176058%20AND%20SRC:MED&resulttype=core&format=json

retrieved

13 April 2020

publication date

1 March 2020

1 reference

stated in

Europe PubMed Central

PubMed publication ID

32176058

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32176058%20AND%20SRC:MED&resulttype=core&format=json

retrieved

13 April 2020

published in

Medicine

1 reference

stated in

Europe PubMed Central

PubMed publication ID

32176058

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32176058%20AND%20SRC:MED&resulttype=core&format=json

retrieved

13 April 2020

volume

99

1 reference

stated in

Europe PubMed Central

PubMed publication ID

32176058

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32176058%20AND%20SRC:MED&resulttype=core&format=json

retrieved

13 April 2020

issue

11

1 reference

stated in

Europe PubMed Central

PubMed publication ID

32176058

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32176058%20AND%20SRC:MED&resulttype=core&format=json

retrieved

13 April 2020

page(s)

e19367

1 reference

stated in

Europe PubMed Central

PubMed publication ID

32176058

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32176058%20AND%20SRC:MED&resulttype=core&format=json

retrieved

13 April 2020

cites work

Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/32176058

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/32176058

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/32176058

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of CTLA-4 in the regulation and initiation of T-cell responses

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/32176058

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of programmed death 1 ligands by murine T cells and APC

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/32176058

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PD-1 and its ligands in tolerance and immunity

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/32176058

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of PD-1 in Regulating T-Cell Immunity

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/32176058

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/32176058

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/32176058

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/32176058

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune Checkpoint Blockade in Cancer Therapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/32176058

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Coinhibitory Pathways in Immunotherapy for Cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/32176058

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/32176058

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/32176058

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/32176058

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/32176058

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/32176058

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1097/MD.0000000000019367

1 reference

stated in

Europe PubMed Central

PubMed publication ID

32176058

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32176058%20AND%20SRC:MED&resulttype=core&format=json

retrieved

13 April 2020

PMC publication ID

7220411

0 references

PubMed publication ID

32176058

1 reference

stated in

Europe PubMed Central

PubMed publication ID

32176058

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32176058%20AND%20SRC:MED&resulttype=core&format=json

retrieved

13 April 2020

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q90352646&oldid=1986048125"